Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
about
IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cellsNanomedicine therapeutic approaches to overcome cancer drug resistanceDiscovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/DoxLymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibodyClinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancerSTAT signaling in the pathogenesis and treatment of cancerPreoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinomaNatriuretic peptide receptor a as a novel target for prostate cancerThe role of interleukin-6 in malignant mesotheliomaCytokine profiling of docetaxel-resistant castration-resistant prostate cancer.Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancersInterleukin-6 and its receptor, key players in hepatobiliary inflammation and cancerOptimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspectsAntiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells.Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors.Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies.Novel therapeutic approach: organic arsenical melarsoprol) alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo.IL-6 Inhibition Reduces STAT3 Activation and Enhances the Antitumor Effect of Carboplatin.Mechanisms and insights into drug resistance in cancerHypermethylated in cancer 1(HIC1) suppresses non-small cell lung cancer progression by targeting interleukin-6/Stat3 pathway.SUMOylation of TBL1 and TBLR1 promotes androgen-independent prostate cancer cell growthIL-6/IL-6R as a potential key signaling pathway in prostate cancer development.Proinflammatory cytokine interleukin-6 in prostate carcinogenesisSTAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug ResistanceOligo-Fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression.IL-6 gene amplification and expression in human glioblastomas.Indoleamine-2,3-dioxygenase and Interleukin-6 associated with tumor response to neoadjuvant chemotherapy in breast cancer.Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain.Characterization of Apoptosis in a Breast Cancer Cell Line after IL-10 SilencingExosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer.Enhancement of antiproliferative effects of interleukin-1beta and tumor necrosis factor-alpha on human prostate cancer LNCaP cells by coculture with normal fibroblasts through secreted interleukin-6.Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment.
P2860
Q24794588-36360AC5-4416-4ABB-B71A-F996704BA5C5Q27011692-835386D1-04F0-4FB6-9EB3-672A0223D668Q28477021-25C56DF0-0A70-439F-97DE-C36DB3C4E574Q28750048-81A0838B-4589-47F8-9853-1E234434C407Q33389676-D9235EA1-DAC0-4E9A-9424-F100A940408CQ33712802-8FA985CA-A6AE-47E7-BB05-0D6820E22262Q34623313-6A0428CD-0E40-4C5E-AD58-A0C043DB1606Q35064001-CB8C2CB2-3CFA-4034-9BEF-029C38072B48Q35200628-62AA6D91-9D47-4DDE-B9A9-562B90657860Q35475443-366CD0EE-5A0F-423F-9112-2C91C7268CFEQ35677625-518AB581-F8D1-4C24-BEE7-55E905C034DAQ36042724-C4F4500E-30BC-4079-9704-14A312BC4B03Q36083211-13CC7B5D-703E-4642-8EF2-A77B42997A15Q36211542-8075C48E-4B29-456D-B4AC-9CB5188D10F7Q36438413-D97A6472-A4F1-45B9-B883-0450A86E7221Q36608759-583B38C5-3A3B-498E-8509-AF360945A7EEQ36621084-FAE6B577-5174-468A-AB51-23CFA00D947AQ36661347-6EE3FC6E-5634-4D02-8BA4-8A5A23B0C2AAQ36682301-033FEAEC-28E4-4D08-BE61-808A8EDB2ECAQ37327489-491CC29E-E4AF-4105-BC79-4F67ABF23D4DQ37520164-EE87C1DF-E034-4DC9-8327-01AED4EDE086Q37968599-CA8B27AD-E638-4790-9F93-4ED6CE9817E9Q38265575-2F54FCE5-1F36-4842-AD45-69F76DCA4790Q38536624-B54BB4F1-BEAE-4D29-B135-BAC1BEF9A744Q41717692-D16B8F16-1591-4476-9FCE-4535307F3C8CQ43202792-F2DA2EED-C829-427E-A0DB-4F69D8DD0900Q47157830-EABE7291-BDF0-480C-A8C8-64A5F9F0B0F9Q47557846-BC94193C-9032-4910-B56B-288CB10C04FCQ52628573-CEF562F6-BDB2-41E9-9ABD-C15422C00C79Q54980135-65C0EF7E-9A24-4348-A141-E08389753C55Q55333263-95133919-6F38-4481-B246-14121531CB53Q55396890-A4B8AD74-F7CE-4479-BBE4-E073A645D1D8
P2860
Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Endogenous interleukin 6 is a ...... prostate carcinoma cell lines.
@en
Endogenous interleukin 6 is a ...... prostate carcinoma cell lines.
@nl
type
label
Endogenous interleukin 6 is a ...... prostate carcinoma cell lines.
@en
Endogenous interleukin 6 is a ...... prostate carcinoma cell lines.
@nl
prefLabel
Endogenous interleukin 6 is a ...... prostate carcinoma cell lines.
@en
Endogenous interleukin 6 is a ...... prostate carcinoma cell lines.
@nl
P2093
P1433
P1476
Endogenous interleukin 6 is a ...... prostate carcinoma cell lines
@en
P2093
Belldegrun A
Bonavida B
Borsellino N
P304
P407
P577
1995-10-01T00:00:00Z